The global epigenetic drugs and diagnostic technologies market was valued at USD 1.6 billion in 2011 and is estimated to reach a market worth USD 5.7 billion in 2018 at a CAGR of 19.4% from 2012 to 2018. The growth of the epigenetics market is driven by factors such as increase in aging population, as there is a strong correlation between cancer and aging. According to WHO, it is estimated that global population over the age of 60 years would double from 11% (2000) to 22% (2050). People aged 60 and above are more prone to cancer. Hence, countries are advocating early detection of cancer through screening kits (Epi Procolon, Epi ProLung) which are driving the epigenetic drugs and diagnostic technologies market. Browse Report : http://www.transparencymarketresearch.com/epigenetics-market.html

1. REPORT DESCRIPTION
Epigenetics Drugs and Diagnostic Technologies Market is Expected to Reach USD
5.7 Billion Globally in 2018
According to a new market report published by Transparency Market Research
"Epigenetics Drugs and Diagnostic Technologies Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the global
epigenetic drugs and diagnostic technologies market was valued at USD 1.6 billion in 2011
and is estimated to reach a market worth USD 5.7 billion in 2018 at a CAGR of 19.4% from
2012 to 2018.
The growth of the epigenetics market is driven by factors such as increase in aging
population, as there is a strong correlation between cancer and aging. According to WHO, it
is estimated that global population over the age of 60 years would double from 11% (2000)
to 22% (2050). People aged 60 and above are more prone to cancer. Hence, countries are
advocating early detection of cancer through screening kits (Epi Procolon, Epi ProLung)
which are driving the epigenetic drugs and diagnostic technologies market.
Transparency Market Research
Epigenetics Drugs and
Diagnostic Technologies
Market - Global Industry
Analysis, Size, Share,
Growth, Trends and
Forecast 2012 - 2018
Single User License: US $ 4595
Multi User License: US $ 7595
Corporate User License: US $ 10595
Buy Now
Request Sample
Published Date: June 2013
112 Pages Report

2. Browse Report : Epigenetics Drugs and Diagnostic Technologies Market
Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to
various disease states. The inhibitors, DNA methyltransferase (DNMT) and Histone
Deacetylase (HDAC) are responsible for regulating the cellular expression. Out of the two
inhibitors, DNMT accounts for a larger share as these inhibitors offer an improved access for
targeting the cancerous cells. Currently, four drugs are approved by FDA and are
commercially available. Two of them are DNMT inhibitors: Celgene's Vidaza (azacitidine)
and Eisai's Dacogen (decitabine) for the treatment of Myelodysplastic Syndrome (MDS), and
the other two are HDAC inhibitors: Merck's Zolinza (vorinostat) and Celgene's Istodax
(romidepsin) both for treatment of Cutaneous T Cell Lymphoma (CTCL).
Epigenetics is a rapidly developing field not only in oncology but also in non-oncology
indications (Alzheimer's and arthritis). Due to the increase in disease identification,
manufacturers are taking initiatives in development of varied epigenetic diagnostic
techniques. DNA methylation technique in the diagnostic segment accounts for the largest
share as compared to histone modification techniques, as the research on DNA methylation
has been carried out since decades, and is thus mostly preferred. Furthermore, with the
corresponding advancements in research and technology, histone code hypothesis technique
came into existence only in late 1980s. Hence, with the surge in interest, there is also an
increase in investment for the research and development of histone modifications.
North America accounts for the largest share of the epigenetics market. It is expected that
North America will dominate around half of the global epigenetics market due to increasing
incidence of cancer and other non-oncology indications. Oncology and other non-oncology
indications (Alzheimer's and arthritis) are associated with epigenetics; thus the increasing
incidence of cancer supports the growth of the epigenetics market. Asia accounts for nearly
half of the new cancer cases worldwide.
The rising incidence of cancer cases in the Asian region would boost the demand for
epigenetic drugs and diagnostic technologies in this market. Australia, China, Japan and
South Korea are the largest markets for these therapies. Japan dominates the epigenetics
market in Asia-Pacific due to a significant presence of companies in the therapeutics
segment such as Eisai Pharmaceuticals and Oncolys Biopharma. These companies are taking
initiatives for the development and commercialization of epigenetic drugs. Various research
institutes and investments from these companies would drive the epigenetics market.
Some of the key players in this market include Celgene Corporation, Merck, Eisai
Pharmaceuticals, Exact Sciences, Epigenomics and others. Manufacturers are entering into
strategic alliances with numerous research institutions and other players for the
development and commercialization of new and innovative drugs, which might see new
players in the market looking to carve out a share of the market for themselves.
The epigenetics drugs and diagnostic technologies market is segmented as follows:
 Epigenetics Drugs Market, by Mechanism of Action DNMT Inhibitors
 Epigenetics Diagnostic Technologies Market, by Types DNA Methylation

3. Chromatin Immunoprecipitation (ChIP) Technology
 Epigenetics Technologies Market, by Geography North America, Europe
Asia-Pacific,RoW
TABLE OF CONTENTS
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Epigenetics Market (2011 & 2018)
2.2 Global Epigenetics Market, by Segments, 2011 (USD Million)
Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
3.2.1 Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
3.2.2 Huge Amounts of Investment
3.2.3 Advances in Screening Tools
3.2.4 Impact Analysis of Market Drivers
3.3 Market Restraints
3.3.1 Genericization of Major Drugs
3.3.2 Impact Analysis of Market Restraints
3.4 Market Opportunities
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Buyers

4. Browse Report : http://www.transparencymarketresearch.com/epigenetics-
market.html
3.5.2 Bargaining Power of Suppliers
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitutes
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis
Chapter 4 Epigenetics Drugs Market, By Mechanism Of Action
4.1 Overview
4.1.1 Global Epigenetic Drugs Market, By Mechanism Of Action, 2010 – 2018 (USD
Million)
4.1.2 Histone Deacetylase (HDAC) Inhibitors
4.1.3 Global HDAC Inhibitors Market, By Drugs, 2010 – 2018 (USD Million)
4.1.3.1 Vorinostat
4.1.3.2 Global Vorinostat Market, By Types 2010 – 2018 (USD Million)
4.1.3.3 Romidepsin
4.1.3.4 Global Romidepsin Market, By Types 2010 – 2018 (USD Million)
4.1.4 DNA Methyltransferase (DNMT) Inhibitors
4.1.5 Global DNMT Inhibitors Market, By Drugs, 2010–2018 (USD Million)
4.1.5.1 Decitabine
4.1.5.2 Global Decitabine Market, By Types 2010 – 2018 (USD Million)
4.1.5.3 Azacitidine
4.1.5.4 Global Azacitidine Market, By Types 2010 – 2018 (USD Million)
4.1.6 Pipeline Drugs
4.1.6.1 Mocetinostat
4.1.6.2 Abexinostat

5. 4.1.6.3 Resminostat
4.1.6.4 Rocilinostat
4.1.6.5 CHR 3996
4.1.6.6 EVP 0334
4.1.6.7 Panobinostat
4.1.6.8 Belinostat
4.1.6.9 Entinostat
4.1.6.10 Valproic Acid
4.1.6.11 Histone Methyltransferase (HMT) Inhibitors
Chapter 5 Epigenetics Diagnostic Technology Market, By Types
5.1 Overview
5.1.1 Global Epigenetic Diagnostic Technologies Market, By Types, 2010 – 2018 (USD
Million)
5.2 DNA Methylation
5.2.1.1 Global DNA Methylation Technology Market, By Types 2010 – 2018 (USD
Million)
5.2.2 Chromatin Immunoprecipitation (Chip)
5.2.2.1 Global Chromatin Immunoprecipitation (Chip) Technology Market, By
Types 2010 – 2018 (USD Million)
Chapter 6 Global Epigenetics Technologies Market, By Geography
6.1 Overview
6.1.1 Global Epigenetics Technologies Market, By Geography, 2010–2018 (USD Million)
6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018
(Value %)
6.3 North America
6.3.1 North America Epigenetics Technologies Market, By Geography, 2010 – 2018
(USD Million)

6. Browse Report : http://www.transparencymarketresearch.com/epigenetics-
market.html
6.4 Europe
6.4.1 Europe Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD
Million)
6.5 Asia-Pacific
6.5.1 Asia-Pacific Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD
Million)
6.6 Rest of the World
6.6.1 Row Epigenetics Technologies Market, By Geography, 2010 – 2018 (USD Million)
Chapter 7 Competitive Landscape
7.1 Market Share Analysis, By Key Players (%)
Chapter 8 Recommendations
8.1 Market Strategy for Success
8.2 Barriers to be Considered
Chapter 9 Company Profiles
9.1 4SC AG
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Overview
9.1.4 Business Strategy
9.1.5 Recent Developments
9.2 Acetylon Pharmaceuticals, Inc.
9.2.1 Company Overview

7. 9.2.2 Financial Overview
9.2.3 Product Overview
9.2.4 Business Strategy
9.2.5 Recent Developments
9.3 Astex Pharmaceuticals Inc.
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategy
9.3.5 Recent Developments
9.4 Cellcentric Ltd.
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategy
9.4.5 Recent Developments
9.5 Celleron Therapeutics Ltd.
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategy
9.6 Celgene Corporation
9.6.1 Business Overview
9.6.2 Financial Overview
9.6.3 Business Strategy
9.6.4 Recent Developments
9.7 Chroma Therapeutics Ltd.

8. Browse Report : http://www.transparencymarketresearch.com/epigenetics-
market.html
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Overview
9.7.4 Business Strategy
9.7.5 Recent Developments
9.8 Epigentek Group Inc.
9.8.1 Business Overview
9.8.2 Financial Overview
9.8.3 Business Strategy
9.8.4 Recent Developments
9.9 Eisai Co. Ltd.
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategy
9.9.5 Recent Developments
9.10 Envivo Pharmaceuticals Inc.
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategy
9.11 Epizyme, Inc.
9.11.1 Company Overview
9.11.2 Financial Overview

9. 9.11.3 Product Portfolio
9.11.4 Business Strategy
9.11.5 Recent Developments
9.12 Illumina Inc.
9.12.1 Company Overview
9.12.2 Financial Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.12.5 Recent Developments
9.13 Mdxhealth
9.13.1 Company Overview
9.13.2 Financial Overview
9.13.3 Product Portfolio
9.13.4 Business Strategy
9.13.5 Recent Developments
9.14 Merck & Company Inc.
9.14.1 Company Overview
9.14.2 Financial Overview
9.14.3 Product Portfolio
9.14.4 Business Strategy
9.15 Novartis International AG
9.15.1 Company Overview
9.15.2 Financial Overview
9.15.3 Product Portfolio
9.15.4 Business Strategy
9.15.5 Mergers And Acquisitions
9.16 Oncolys Biopharma Inc.

10. Browse Report : http://www.transparencymarketresearch.com/epigenetics-
market.html
9.16.1 Company Overview
9.16.2 Financial Overview
9.16.3 Product Portfolio
9.16.4 Business Strategy
9.17 Pharmacyclics, Inc.
9.17.1 Company Overview
9.17.2 Financial Overview
9.17.3 Product Portfolio
9.17.4 Business Strategy
9.17.5 Recent Developments
9.18 Promega Corporation
9.18.1 Company Overview
9.18.2 Financial Overview
9.18.3 Product Portfolio
9.18.4 Business Strategy
9.18.5 Recent Developments
9.19 Repligen Corporation
9.19.1 Company Overview
9.19.2 Financial Overview
9.19.3 Product Portfolio
9.19.4 Business Strategy
9.19.5 Recent Developments
9.20 Spectrum Pharmaceuticals
9.20.1 Company Overview

11. 9.20.2 Financial Overview
9.20.3 Product Portfolio
9.20.4 Business Strategy
9.20.5 Recent Developments
9.21 Syndax Pharmaceuticals, Inc.
9.21.1 Company Overview
9.21.2 Financial Overview
9.21.3 Product Portfolio
9.21.4 Business Strategy
9.21.5 Recent Developments
9.22 Topotarget A/S
9.22.1 Company Overview
9.22.2 Financial Overview
9.22.3 Product Portfolio
9.22.4 Business Strategy
9.22.5 Recent Developments
9.23 Valirx Plc
9.23.1 Company Profile
9.23.2 Financial Overview
9.23.3 Product Portfolio And Technology
9.23.4 Business Strategy
9.23.5 Recent Developments
About Us:
Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.

12. We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/